This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BioMarin (BMRN) Starts Restructuring Moves to Increase Efficiency
by Zacks Equity Research
BioMarin (BMRN) intends to reduce the existing workforce by nearly 4%. The company plans to use the savings in costs and redirect them toward its operating expenses.
BioMarin (BMRN) Refiles BLA With FDA for Hemophilia Gene Therapy
by Zacks Equity Research
If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will be the first gene therapy for hemophilia A in the United States. The FDA filing also incorporates BMRN's responses to the CRL issued to the BLA in 2020.
Why Is BioMarin (BMRN) Down 2.3% Since Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioMarin's (BMRN) Hemophilia Gene Therapy Gets Nod in EU
by Zacks Equity Research
BioMarin's (BMRN) Roctavian is the first gene therapy to get approval for hemophilia A in the European Union. The therapy has also been granted a 10-year market exclusivity.
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal
by Zacks Equity Research
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
Roche (RHHBY) Influenza Drug Gets FDA Nod for Children
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.
CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.
Clearwater Paper and Logitech International have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Clearwater Paper and Logitech International are part of as Zacks Bull and Bear of the Day article.
Four Giant Tech Groups Keep the S&P 500 Aloft: Zacks August Market Strategy
by John Blank
The S&P 500 index -- and the broader underlying U.S. economy -- is now tied directly to the success of just four major converging, tech business groups.
BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales
by Zacks Equity Research
Biomarin Pharmaceutical's (BMRN) second-quarter earnings and sales beat estimates. BMRN slightly raises its sales guidance for the year.
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Factors to Note Ahead of Humana (HUM) Q2 Earnings Release
by Zacks Equity Research
Humana's (HUM) second-quarter results are likely to reflect higher premiums from the Retail segment and overall membership growth, partly offset by elevated technology-linked investments.
Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint
by Zacks Equity Research
Novo Nordisk's (NVO) phase I & II FRONTIER1 dose-escalation study investigating Mim8 for treating people with haemophilia A meets its primary safety endpoint.
BioMarin (BMRN) Gets CHMP Nod for Hemophilia Drug Roctavian
by Zacks Equity Research
BioMarin (BMRN) receives a positive CHMP opinion for Roctavian, its gene therapy for treating adults with hemophilia A. The European Commission's decision is expected by the third quarter of 2022.
BioMarin (BMRN) Stock Jumps 5.4%: Will It Continue to Soar?
by Zacks Equity Research
BioMarin (BMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug
by Zacks Equity Research
BioMarin (BMRN) posts follow-up data from a phase I/II study on its gene-therapy candidate for hemophilia A. However, the stock falls 7% as management plans to defer the candidate's BLA filing.
BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected results for Q1. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
ResMed (RMD) Q3 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.
Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View
by Zacks Equity Research
Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues. Shares down.
BioMarin (BMRN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Biomarin Pharmaceutical's (BMRN) first-quarter earnings and sales beat estimates. BMRN also raises its financial guidance for 2022 Voxzogo sales by $10 million.
Alkermes (ALKS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Alkermes (ALKS) rides high on both earnings and sales beating estimates in the first quarter of 2022.
BioMarin Pharmaceutical (BMRN) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 44.74% and 2.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?